Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 106 articles:
HTML format

Single Articles

    May 2024
  1. DAVER NG, Craddock C
    Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome.
    J Clin Oncol. 2024;42:1731-1733.

  2. WANG ES, Goldberg AD, Tallman M, Walter RB, et al
    Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1776-1787.
    PubMed     Abstract available

  3. VAN DER SLUIS IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, et al
    Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
    J Clin Oncol. 2024;42:1676-1686.
    PubMed     Abstract available

  4. SHORT NJ, Daver N, Dinardo CD, Kadia T, et al
    Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1499-1508.
    PubMed     Abstract available

    April 2024
  5. TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
    Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    J Clin Oncol. 2024;42:1378-1390.
    PubMed     Abstract available

  6. RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al
    Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
    J Clin Oncol. 2024;42:1158-1168.
    PubMed     Abstract available

    March 2024
  7. BERMAN E, Shah NP, Deninger M, Altman JK, et al
    CML and the WHO: Why?
    J Clin Oncol. 2024;42:984-986.

  8. FEDELE PL, Opat S
    Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
    J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.

  9. LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al
    Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
    PubMed     Abstract available

  10. MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al
    European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
    J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
    PubMed     Abstract available

  11. FOA R, Bassan R, Elia L, Piciocchi A, et al
    Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
    J Clin Oncol. 2024;42:881-885.
    PubMed     Abstract available

  12. CONTER V, Valsecchi MG, Cario G, Zimmermann M, et al
    Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
    J Clin Oncol. 2024;42:915-926.
    PubMed     Abstract available

  13. HODDER A, Mishra AK, Enshaei A, Baird S, et al
    Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
    J Clin Oncol. 2024;42:907-914.
    PubMed     Abstract available

    January 2024
  14. LOGAN A
    Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
    J Clin Oncol. 2024;42:250-252.

  15. STELLJES M, Raffel S, Alakel N, Wasch R, et al
    Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
    J Clin Oncol. 2024;42:273-282.
    PubMed     Abstract available

  16. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    PubMed     Abstract available

    December 2023
  17. PIETERS R, Mullighan CG, Hunger SP
    Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.
    J Clin Oncol. 2023;41:5579-5591.
    PubMed     Abstract available

  18. LEE SHR, Ashcraft E, Yang W, Roberts KG, et al
    Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.
    J Clin Oncol. 2023;41:5422-5432.
    PubMed     Abstract available

  19. RASHIDI A, Ebadi M, Rehman TU, Elhusseini H, et al
    Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
    J Clin Oncol. 2023;41:5306-5319.
    PubMed     Abstract available

    November 2023
  20. BRIVIO E, Pennesi E, Willemse ME, Huitema ADR, et al
    Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
    J Clin Oncol. 2023 Nov 30:JCO2300897. doi: 10.1200/JCO.23.00897.
    PubMed     Abstract available

  21. RAETZ EA, Rebora P, Conter V, Schrappe M, et al
    Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
    J Clin Oncol. 2023;41:5025-5034.
    PubMed     Abstract available

  22. DAVER NG, Vyas P, Kambhampati S, Al Malki MM, et al
    Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
    J Clin Oncol. 2023;41:4893-4904.
    PubMed     Abstract available

  23. LI J, Gao J, Liu A, Liu W, et al
    Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
    J Clin Oncol. 2023;41:4881-4892.
    PubMed     Abstract available

    October 2023
  24. DEWOLF S, Tallman MS, Rowe JM, Salman MY, et al
    What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
    J Clin Oncol. 2023;41:4693-4703.
    PubMed     Abstract available

  25. LING Y, Xuan L, Xu N, Huang F, et al
    Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    J Clin Oncol. 2023;41:4632-4642.
    PubMed     Abstract available

    September 2023
  26. MCCAW ZR, Richardson PG, Wei LJ
    Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML.
    J Clin Oncol. 2023;41:4446-4447.

  27. Erratum: Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
    J Clin Oncol. 2023 Sep 12:JCO2301844. doi: 10.1200/JCO.23.01844.

  28. PRATZ KW, Cherry M, Altman JK, Cooper BW, et al
    Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
    J Clin Oncol. 2023;41:4236-4246.
    PubMed     Abstract available

  29. PIETERS R, de Groot-Kruseman H, Fiocco M, Verwer F, et al
    Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
    J Clin Oncol. 2023;41:4130-4142.
    PubMed     Abstract available

    July 2023
  30. MUNIR T, Moreno C, Owen C, Follows G, et al
    Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
    J Clin Oncol. 2023;41:3689-3699.
    PubMed     Abstract available

  31. ARIFFIN H, Chiew EKH, Oh BLZ, Lee SHR, et al
    Anthracycline-Free Protocol for Favorable-Risk Childhood ALL: A Noninferiority Comparison Between Malaysia-Singapore ALL 2003 and ALL 2010 Studies.
    J Clin Oncol. 2023;41:3642-3651.
    PubMed     Abstract available

    June 2023
  32. KIPPS TJ
    Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2023 Jun 6:JCO2300619. doi: 10.1200/JCO.23.00619.

    May 2023
  33. SALLMAN DA, Al Malki MM, Asch AS, Wang ES, et al
    Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
    J Clin Oncol. 2023;41:2815-2826.
    PubMed     Abstract available

  34. RIBEIRO RC, Conter V
    Optimizing Pediatric Leukemia Care in Countries With Limited Resources.
    J Clin Oncol. 2023 May 4:JCO2300451. doi: 10.1200/JCO.23.00451.

  35. CAMPBELL M, Kiss C, Zimmermann M, Riccheri C, et al
    Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Munster 2009 Trial.
    J Clin Oncol. 2023 May 4:JCO2201760. doi: 10.1200/JCO.22.01760.
    PubMed     Abstract available

    April 2023
  36. O'CONNOR D, Demeulemeester J, Conde L, Kirkwood A, et al
    The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2023 Apr 25:JCO2202734. doi: 10.1200/JCO.22.02734.
    PubMed     Abstract available

  37. CHOW EJ, Aggarwal S, Doody DR, Aplenc R, et al
    Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
    J Clin Oncol. 2023;41:2248-2257.
    PubMed     Abstract available

  38. EAPEN M, Brazauskas R, Williams DA, Walters MC, et al
    Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
    J Clin Oncol. 2023;41:2227-2237.
    PubMed     Abstract available

    March 2023
  39. VAN WEELDEREN RE, Klein K, Harrison CJ, Jiang Y, et al
    Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Munster Study Group.
    J Clin Oncol. 2023 Mar 30:JCO2202120. doi: 10.1200/JCO.22.02120.
    PubMed     Abstract available

  40. TONG WH, Mertens BJ
    More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
    J Clin Oncol. 2023 Mar 10:JCO2202839. doi: 10.1200/JCO.22.02839.

    How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
    J Clin Oncol. 2023;41:1342-1349.
    PubMed     Abstract available

    February 2023
  42. FARRAR JE, Smith JL, Othus M, Huang BJ, et al
    Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
    J Clin Oncol. 2023 Feb 16:JCO2201114. doi: 10.1200/JCO.22.01114.
    PubMed     Abstract available

    January 2023
  43. CRIVELLO P, Arrieta-Bolanos E, He M, Wang T, et al
    Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation.
    J Clin Oncol. 2023 Jan 20:JCO2201229. doi: 10.1200/JCO.22.01229.
    PubMed     Abstract available

  44. SMYTH E, Eyre TA, Cheah CY
    Emerging Therapies for the Management of Richter Transformation.
    J Clin Oncol. 2023;41:395-409.
    PubMed     Abstract available

  45. SHIBUSAWA M, Tanimoto T
    Conditioning Regimen in Patients With Adult Acute B Lymphoblastic Leukemia.
    J Clin Oncol. 2023 Jan 3:JCO2202230. doi: 10.1200/JCO.22.02230.

    December 2022
  46. ITZYKSON R, Santini V, Thepot S, Ades L, et al
    Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
    J Clin Oncol. 2022 Dec 1:JCO2200437. doi: 10.1200/JCO.22.00437.
    PubMed     Abstract available

    November 2022
  47. LAETSCH TW, Maude SL, Rives S, Hiramatsu H, et al
    Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
    J Clin Oncol. 2022 Nov 18:JCO2200642. doi: 10.1200/JCO.22.00642.
    PubMed     Abstract available

  48. HILLMEN P, Eichhorst B, Brown JR, Lamanna N, et al
    Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200/JCO.22.00510.
    PubMed     Abstract available

  49. CASEY M, Odhiambo L, Aggarwal N, Shoukier M, et al
    Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?
    J Clin Oncol. 2022;40:3719-3729.
    PubMed     Abstract available

  50. WANG T, Tang Y, Cai J, Wan X, et al
    Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    J Clin Oncol. 2022 Nov 8:JCO2201214. doi: 10.1200/JCO.22.01214.
    PubMed     Abstract available

  51. JACOLA LM, Conklin HM, Krull KR, Pei D, et al
    The Impact of Intensified CNS-Directed Therapy on Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
    J Clin Oncol. 2022 Nov 2:JCO2200263. doi: 10.1200/JCO.22.00263.
    PubMed     Abstract available

    October 2022
  52. GROB T, Sanders MA, Vonk CM, Kavelaars FG, et al
    Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Oct 31:JCO2200715. doi: 10.1200/JCO.22.00715.
    PubMed     Abstract available

  53. JELINEK T, Bezdekova R, Zihala D, Sevcikova T, et al
    More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
    J Clin Oncol. 2022 Oct 31:JCO2201226. doi: 10.1200/JCO.22.01226.
    PubMed     Abstract available

  54. LAMPSON BL, Gupta A, Tyekucheva S, Mashima K, et al
    Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Oct 31:JCO2200269. doi: 10.1200/JCO.22.00269.
    PubMed     Abstract available

  55. ATTARBASCHI A, Moricke A, Harrison CJ, Mann G, et al
    Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study.
    J Clin Oncol. 2022 Oct 18:JCO2201297. doi: 10.1200/JCO.22.01297.
    PubMed     Abstract available

    September 2022
  56. SCHULTZ LM, Eaton A, Baggott C, Rossoff J, et al
    Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Sep 15:JCO2201076. doi: 10.1200/JCO.22.01076.
    PubMed     Abstract available

  57. ZHANG H, Fan Z, Huang F, Han L, et al
    Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
    J Clin Oncol. 2022 Sep 9:JCO2200767. doi: 10.1200/JCO.22.00767.
    PubMed     Abstract available

    August 2022
  58. SOCIE G
    Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia.
    J Clin Oncol. 2022 Aug 5:JCO2201177. doi: 10.1200/JCO.22.01177.
    PubMed     Abstract available

    July 2022
  59. DAVER N, Perl AE, Maly J, Levis M, et al
    Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jul 18:JCO2200602. doi: 10.1200/JCO.22.00602.
    PubMed     Abstract available

  60. MISHRA A, Tamari R, DeZern AE, Byrne MT, et al
    Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    J Clin Oncol. 2022 Jul 11:JCO2200181. doi: 10.1200/JCO.22.00181.
    PubMed     Abstract available

    June 2022
  61. ARMENIAN SH, Chen Y, Hageman L, Wu J, et al
    Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
    J Clin Oncol. 2022 Jun 22:JCO2102829. doi: 10.1200/JCO.21.02829.
    PubMed     Abstract available

  62. MOORMAN AV, Antony G, Wade R, Butler ER, et al
    Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
    J Clin Oncol. 2022 Jun 17:JCO2200245. doi: 10.1200/JCO.22.00245.
    PubMed     Abstract available

  63. KADIA TM, Reville PK, Wang X, Rausch CR, et al
    Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jun 15:JCO2102823. doi: 10.1200/JCO.21.02823.
    PubMed     Abstract available

  64. HANTEL A, Kohlschmidt J, Eisfeld AK, Stock W, et al
    Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
    J Clin Oncol. 2022 Jun 13:JCO2200307. doi: 10.1200/JCO.22.00307.
    PubMed     Abstract available

  65. CHIHARA D, Huang EP, Finnigan SR, Cordes LM, et al
    Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
    J Clin Oncol. 2022;40:1949-1957.
    PubMed     Abstract available

    May 2022
  66. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    PubMed     Abstract available

    April 2022
  67. PERL AE
    Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition.
    J Clin Oncol. 2022 Apr 18:JCO2200499. doi: 10.1200/JCO.22.00499.

  68. CHANG A, Akhtar A, Linderman SL, Lai L, et al
    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Apr 18:JCO2200088. doi: 10.1200/JCO.22.00088.
    PubMed     Abstract available

  69. BLEAKLEY M, Sehgal A, Seropian S, Biernacki MA, et al
    Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
    J Clin Oncol. 2022;40:1174-1185.
    PubMed     Abstract available

  70. WALSH BS, Kesselheim AS, Sarpatwari A, Rome BN, et al
    Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
    J Clin Oncol. 2022;40:1102-1110.
    PubMed     Abstract available

    March 2022
  71. HOFSTE OP BRUININK D, Kuiper R, van Duin M, Cupedo T, et al
    Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
    J Clin Oncol. 2022 Mar 31:JCO2101217. doi: 10.1200/JCO.21.01217.
    PubMed     Abstract available

  72. POLLARD JA, Alonzo TA, Gerbing R, Brown P, et al
    Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.
    J Clin Oncol. 2022 Mar 29:JCO2101612. doi: 10.1200/JCO.21.01612.
    PubMed     Abstract available

  73. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed     Abstract available

  74. TEACHEY DT, Devidas M, Wood BL, Chen Z, et al
    Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200/JCO.21.02678.
    PubMed     Abstract available

    February 2022
  75. ADVANI AS, Moseley A, O'Dwyer KM, Wood BL, et al
    SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200/JCO.21.01766.
    PubMed     Abstract available

    January 2022
    Toward Personalization of Cytarabine Dosing in Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jan 13:JCO2102723. doi: 10.1200/JCO.21.02723.

  77. O'BRIEN MM, Ji L, Shah NN, Rheingold SR, et al
    Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
    J Clin Oncol. 2022 Jan 10:JCO2101693. doi: 10.1200/JCO.21.01693.
    PubMed     Abstract available

  78. DINARDO CD, Pollyea DA
    Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy.
    J Clin Oncol. 2022 Jan 10:JCO2102762. doi: 10.1200/JCO.21.02762.

  79. GIBSON CJ, Kim HT, Zhao L, Murdock HM, et al
    Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
    J Clin Oncol. 2022;40:189-201.
    PubMed     Abstract available

  80. ELSAYED AH, Cao X, Mitra AK, Wu H, et al
    Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    J Clin Oncol. 2022 Jan 6:JCO2101422. doi: 10.1200/JCO.21.01422.
    PubMed     Abstract available

    December 2021
  81. PRATZ KW, Jonas BA, Pullarkat V, Recher C, et al
    Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine.
    J Clin Oncol. 2021 Dec 15:JCO2101546. doi: 10.1200/JCO.21.01546.
    PubMed     Abstract available

  82. NORSWORTHY KJ, Gao X, Ko CW, Pulte ED, et al
    Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
    J Clin Oncol. 2021 Dec 10:JCO2101548. doi: 10.1200/JCO.21.01548.
    PubMed     Abstract available

  83. SCHULTZ LM, Baggott C, Prabhu S, Pacenta HL, et al
    Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    J Clin Oncol. 2021 Dec 9:JCO2003585. doi: 10.1200/JCO.20.03585.
    PubMed     Abstract available

  84. LAMBLE AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, et al
    CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2021 Dec 2:JCO2101595. doi: 10.1200/JCO.21.01595.
    PubMed     Abstract available

    October 2021
  85. NAKAMURA R, Saber W, Martens MJ, Ramirez A, et al
    Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
    J Clin Oncol. 2021;39:3328-3339.
    PubMed     Abstract available

  86. WIERDA WG, Allan JN, Siddiqi T, Kipps TJ, et al
    Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    J Clin Oncol. 2021 Oct 7:JCO2100807. doi: 10.1200/JCO.21.00807.
    PubMed     Abstract available

  87. POLLARD JA, Guest E, Alonzo TA, Gerbing RB, et al
    Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
    J Clin Oncol. 2021;39:3149-3160.
    PubMed     Abstract available

    August 2021
  88. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Aug 31:JCO2100917. doi: 10.1200/JCO.21.00917.
    PubMed     Abstract available

  89. ABDEL-QADIR H, Sabrie N, Leong D, Pang A, et al
    Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    J Clin Oncol. 2021 Aug 31:JCO2100693. doi: 10.1200/JCO.21.00693.
    PubMed     Abstract available

  90. SHORT NJ, Kantarjian H
    When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era.
    J Clin Oncol. 2021 Aug 18:JCO2100960. doi: 10.1200/JCO.21.00960.

    July 2021
  91. PAN J, Tan Y, Wang G, Deng B, et al
    Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    J Clin Oncol. 2021 Jul 29:JCO2100389. doi: 10.1200/JCO.21.00389.
    PubMed     Abstract available

    Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    J Clin Oncol. 2021 Jul 26:JCO2101414. doi: 10.1200/JCO.21.01414.

  93. BYRD JC, Hillmen P, Ghia P, Kater AP, et al
    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    J Clin Oncol. 2021 Jul 26:JCO2101210. doi: 10.1200/JCO.21.01210.
    PubMed     Abstract available

  94. GUI G, Dillon LW, Hourigan CS
    Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.
    J Clin Oncol. 2021;39:2413-2415.

  95. VROOMAN LM, Blonquist TM, Stevenson KE, Supko JG, et al
    Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
    J Clin Oncol. 2021 Jul 6:JCO2003692. doi: 10.1200/JCO.20.03692.
    PubMed     Abstract available

    June 2021
  96. DESAI PM, Brown J, Gill S, Solh MM, et al
    Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2001739. doi: 10.1200/JCO.20.01739.
    PubMed     Abstract available

  97. MYERS RM, Li Y, Barz Leahy A, Barrett DM, et al
    Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2003458. doi: 10.1200/JCO.20.03458.
    PubMed     Abstract available

  98. WEI AH, Roboz GJ, Kantarjian HM
    Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 4:JCO2100080. doi: 10.1200/JCO.21.00080.

  99. ZHENG H, Jiang H, Hu S, Liao N, et al
    Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
    J Clin Oncol. 2021 Jun 2:JCO2003096. doi: 10.1200/JCO.20.03096.
    PubMed     Abstract available

    May 2021
  100. SHORT NJ, Tallman MS, Pollyea DA, Ravandi F, et al
    Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
    J Clin Oncol. 2021 May 27:JCO2100067. doi: 10.1200/JCO.21.00067.

  101. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2021 May 27:JCO2003736. doi: 10.1200/JCO.20.03736.
    PubMed     Abstract available

  102. SHAH NN, Lee DW, Yates B, Yuan CM, et al
    Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
    J Clin Oncol. 2021;39:1650-1659.
    PubMed     Abstract available

    April 2021
  103. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    PubMed     Abstract available

  104. VAN DER PLAS E, Modi AJ, Li CK, Krull KR, et al
    Cognitive Impairment in Survivors of Pediatric Acute Lymphoblastic Leukemia Treated With Chemotherapy Only.
    J Clin Oncol. 2021 Apr 22:JCO2002322. doi: 10.1200/JCO.20.02322.

    February 2021
  105. RIMANDO JC, Christopher MJ, Rettig MP, DiPersio JF, et al
    Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.
    J Clin Oncol. 2021;39:386-396.

  106. PETERS C, Dalle JH, Locatelli F, Poetschger U, et al
    Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    J Clin Oncol. 2021;39:295-307.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.